Member Info for WildStar

Any ideas about ge3tting away form the reverse timeline and 5 post only showing?

Yep, same for me. Thought I'd changed something but if I haven't then this makes it a nightmare! Anyone have an idea how to revert back from the 'upside down' 5 post only type change?

Don't think this has all the correct formatting, but this is the content from Bella's original link (thanks):

https://www.imperial.ac.uk/news/239811/new-startup-help-pharmaceutical-companies-develop/amp/?amp_gsa=1&_js_v=a9&usqp=mq331AQIUAKwASCAAgM%3D#amp_ct=1695317725268&_tf=From%20%251%24s&aoh=16953176143367&referrer=https%3A%2F%2Fwww.google.com&share=https%3A%2F%2Fwww.imperial.ac.uk%2Fnews%2F239811%2Fnew-startup-help-pharmaceutical-companies-develop%2F

I don't think there's anything new there.

The coding on the page suggests the page was last updated on 29 June.

Ah, of course, forgot I could follow it up with bard.

Follow up Q:

What are your sources for that?

Bard:

My sources for the information about AVA6000 include:

The Avacta Group plc website: https://www.avacta.com/

The Bristol Myers Squibb website: https://www.bms.com/

The Astellas Pharma website: https://www.astellas.com/

The Janssen Pharmaceuticals website: https://www.janssen.com/

The Merck & Co. website: https://www.merck.com/

The Pfizer website: https://www.pfizer.com/

I also used the following scientific papers:

"AVA6000, a novel tumour-targeted form of doxorubicin, is well-tolerated in patients with advanced solid tumours: a Phase 1 dose-escalation study."

"Therapeutic potential of AVA6000, a novel tumour-targeted form of doxorubicin."

"AVA6000: a novel tumour-targeted form of doxorubicin with the potential to reduce systemic side effects."

I hope this helps!

Was interested to see that myself but unfortunatley it didn't cite any sources.

Asked bard.google about AVA6K:

Q: Are any companies interested in ava6000?

Bard: Yes, there are several companies that are interested in AVA6000. In 2021, Avacta Group plc entered into a strategic collaboration with Bristol Myers Squibb (BMS) to develop and commercialize AVA6000 in the United States. BMS is a global pharmaceutical company with a strong track record in cancer drug development. The collaboration with BMS provides Avacta with the resources and expertise to accelerate the development of AVA6000 in the US.

In addition to BMS, there are several other companies that have expressed interest in AVA6000. These companies include:

Astellas Pharma

Janssen Pharmaceuticals

Merck & Co.

Pfizer

These companies are interested in AVA6000 because it has the potential to be a more effective and tolerable treatment option for patients with cancer. If AVA6000 is successful in Phase 2 clinical trials, it is likely that these companies will enter into licensing agreements with Avacta to develop and commercialize AVA6000 in their respective territories.

The development of AVA6000 is a promising new approach to cancer treatment. With the interest of several major pharmaceutical companies, it is likely that AVA6000 will have the opportunity to reach patients in need.

... nice little summamry I thought, and I especially love the last line, "...it is LIKELY that AVA6000 will have the opportunity to reach patients in need."

IG taking new SB again :)

Not entirely Bella. Surely the phase 1a is purely to prove safety... AVCT aren't looking to make any statements about efficacy at this stage (although the just might). I don't think we should raise expectations by suggesting they are required now. I'll be happy with a positive RNS which will raise the SP without a doubt!

'Closing only' on IG as well.

From IG client sentiment:
"95% of IG client accounts with open positions in this market expect the price to rise"

I suspect that means a vast number of the new shares will be held for the rerate.

Wasn't the general consensus recently that we will hear news as and when ready in Q4 and speculation about the actual date was probably best avoided as some may push the, 'it's late and therefore bad news' agenda.

There is no date promised... just expect results in Q4.

I'm more than happy with that thanks.

Nothing to say that new information won't have already been released BEFORE the presentation i.e. Friday...

I have to say that I'm with jmfw on this one.

The recent push with a 'placing coming' from the shorting crew, as we all know, had no real substance.
However, there was indeed a placing, but for entirely different reasons as suggested and ultimately helping to achieve a truly impressive aim.

Did some 'paperwork skivvy' somewhere give the nod to a 3rd party informing them that placing paperwork had been lodged but had no knowleldge of the real reason... hence speculative nonsense promoted by a 3rd party?

It went live today:
https://avacta.com/investors/website-disclaimer/

Unsure what this implies overall though, if anything.

Avacta just posted and then quickly removed a new page on their website
It was a 'website-disclaimer' page whereby the user selected a drop down of which country they were in - global coverage options available.

Interesting...

Obviously they have inside info on the trial data and are NOT allowed to buy... but... if you're trying to push that agenda, they also AREN'T selling either, so all must be good!

@MrA
Exclusivity Vs patent
https://www.raps.org/regulatory-focus%E2%84%A2/news-articles/2016/8/patents-vs-market-exclusivity-why-does-it-take-so-long-to-bring-generics-to-market

@RD
I'm not sure why you've even bothered to post that... er, comment.
Do you not think that THE people that need to know the advantages and disadvantages of AV6K will already be way ahead of us and far more knowledgeable on everything with regards to the treatment?

I'm reasonbly confident (for that read, absolutely positive) that Avacta aren't planning a late night advertising campaign on Dave to launch it!

Excellent - and thanks, as ever, for your informed input.

I kept going through the only documentation I've found for the trial (https://clinicaltrials.gov/ct2/show/study/NCT04969835) but wondered if I'd missed something somewhere else that just might clarify that one single but major point.

I also honestly can't see that it would progress if there wasn't any activation.
I'm still all in!